Sermorelin
GHRH Analog | Growth Hormone Releasing Hormone
Sermorelin is a synthetic 29-amino acid analog of human growth hormone-releasing hormone that stimulates natural growth hormone production while preserving physiological pulsatile patterns. Originally FDA-approved in 1997 for pediatric GH deficiency, it was discontinued in 2008 for manufacturing reasons, not safety concerns.
Mechanism of Action
Subcutaneous injection provides optimal bioavailability for binding GHRH receptors, stimulating pulsatile GH release while maintaining hypothalamic-pituitary axis integrity and allowing natural somatostatin negative feedback.
Key Benefits
- FDA-proven efficacy
- Maintains natural GH pulsatile patterns
- Preserves pituitary function
- 1.26kg lean mass increase documented in elderly
- IGF-1 mediated anabolic effects
- Allows natural feedback regulation
Muscle Growth
- Lean Body Mass Enhancement
1.26kg lean mass increase documented in elderly men with improved muscle strength tests.
- IGF-1 Mediated Growth
Endogenous IGF-1 stimulation drives protein synthesis and muscle growth.
- Athletic Recovery
Enhanced recovery through physiological GH stimulation.
Anti-Aging
- Age-Related GH Decline Reversal
Doubles 12-hour GH release in elderly subjects over 6 weeks.
- Body Composition Improvement
Decreased adiposity and improved lean mass distribution.
- Skin Quality Enhancement
Improved skin thickness and quality.
Hormonal
- Endogenous GH Stimulation
Preserves natural axis function without suppression.
- Natural Pulsatile Secretion
Maintains physiological GH release patterns.
Subcutaneous injection is the primary method. Bedtime administration aligns with natural nocturnal GH pulses. Avoid food 2+ hours before injection as carbohydrates blunt GH response.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Anti-aging/Longevity | 200-300mcg | Once at bedtime | SubQ |
| Athletic Performance | 300-500mcg | Once at bedtime | SubQ |
| Body Composition | 200mcg | 5 days weekly | SubQ |
| Combination Therapy | 200mcg + GHRP | Once daily | SubQ co-injection |
Reconstitution Instructions
- Sermorelin acetate lyophilized powder (2-5mg vial)
- Bacteriostatic water for injection (3mL)
- Insulin syringes (28-30 gauge)
- Alcohol swabs
- 1 Allow vial to reach room temperature
- 2 Clean vial top with alcohol swab; allow to dry
- 3 Inject 3mL bacteriostatic water slowly against vial wall (not directly on powder)
- 4 Gently swirl in circular motion - do not shake vigorously
- 5 Allow 2-3 minutes until powder dissolves into clear solution
- 6 Store reconstituted solution at 2-8°C; use within 10-30 days
- 7 Inject subcutaneously at 45-degree angle; rotate sites
Excellent combination producing 3-5 fold increases in GH release.
Highly effective combination - CJC-1295 provides sustained 6-8 day release while sermorelin offers immediate pulsatile effects.
Combined GHRH+GHRP-2 produces 54-fold GH increases compared to 20-fold with GHRH alone.
Somatostatin analogs directly block GH release by activating inhibitory receptors.
High-dose glucocorticoids suppress pituitary GH release and reduce GHRH receptor sensitivity.
GH antagonizes insulin action; monitor combination closely.
Essential combination as untreated hypothyroidism prevents sermorelin response.
IGF-1 elevation begins; improved sleep quality and recovery
Body composition changes begin; increased energy and well-being
Visible muscle tone improvements; fat reduction; skin quality enhancement
Sustained improvements; optimal IGF-1 elevation
Maximum benefits: muscle growth, fat loss, anti-aging effects
Common Side Effects
- Injection site reactions (16.7% of patients - generally mild)
- Nasal irritation (intranasal route)
Stop Signs - Discontinue if:
- Signs of pituitary tumor growth (headaches, vision changes)
- Severe injection site reactions or generalized allergic responses
- Uncontrolled diabetes or significant glucose intolerance
- New onset or worsening malignancy symptoms
Contraindications
- Active malignancy
- Pituitary tumors
- Pregnancy
Good Signs
- Completely clear and colorless solution without particles, cloudiness, or precipitation
- Greater than 98% peptide purity per USP standards
- Sterile, nonpyrogenic lyophilized powder
- Maintained at 2-8°C throughout transport
- Produced in FDA-registered facilities following cGMP
Warning Signs
- Brief room temperature exposure acceptable up to 72 hours but should be refrigerated promptly
Bad Signs
- Any cloudiness, particles, color changes, or precipitation indicates degradation
- Molecular weight should be exactly 3,358 daltons (free base) or 3,418 daltons (acetate salt)
- FDA Approval Study - Geref International Study Group Trial(1996)
Pivotal trial with 110 prepubertal GH-deficient children demonstrating sustained efficacy through 36 months. Height velocity increased from 4.1 to 8.0 cm/year.
- Adult Anti-Aging Study - Corpas et al.(1992)
Landmark study demonstrating reversal of age-related GH/IGF-1 decline in 60-78 year old males. Doubled 12-hour GH release over 6 weeks.
- Pharmacokinetic Profile(1996)
Comprehensive analysis showing 11-12 minute half-life and 6% bioavailability for subcutaneous administration.
- Body Composition in Elderly(1992)
1.26kg lean mass increase with improved muscle strength; decreased systolic BP.
- Nasal Administration Study(1990)
69% patient preference over injection with reliable therapeutic response at 30+ mcg/kg.
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.